Møller, P R, Kærsgaard, M L, Grydehøj, J & Ovesen, T 2022, ' Normal salivary production using a swab method in clinical settings ', Clinical Otolaryngology, vol. 47, no. 5, pp. 583-588 . https://doi.org/10.1111/coa.13953 Møller, P R, Kærsgaard, M L, Grydehøj, J & Ovesen, T 2022, ' Normal salivary production using a swab method in clinical settings ', Clinical otolaryngology, vol. 47, no. 5, pp. 583-588 . https://doi.org/10.1111/coa.13953
Glintborg, B, Georgiadis, S, Loft, A G, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Andersen, B L, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4) : an observational nationwide study applying linkage between DANBIO and national registries ', Annals of the Rheumatic Diseases, vol. 79, no. 6, pp. 846-848 . https://doi.org/10.1136/annrheumdis-2019-216702 Glintborg, B, Georgiadis, S, Loft, A G R, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Lange Andersen, B, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J L, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries ', Annals of the Rheumatic Diseases, bind 79, nr. 6 . https://doi.org/10.1136/annrheumdis-2019-216702 Glintborg, B, Georgiadis, S, Loft, A G, Linauskas, A, Lindegaard, H, Hendricks, O, Jensen, D V, Andersen, B L, Danebod, K, Villumsen, A, Eng, G, Wiell, C, Manilo, N, Kristensen, S, Raun, J, Grydehøj, J, Chrysidis, S, Nørgaard, M, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4) : An observational nationwide study applying linkage between DANBIO and national registries ', Annals of the rheumatic diseases, vol. 79, no. 6, pp. 846-848 . https://doi.org/10.1136/annrheumdis-2019-216702
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to ''To switch or not to switch' : the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4, e37 . https://doi.org/10.1136/annrheumdis-2018-214952 Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to To switch or not to switch' : The missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4, e37 . https://doi.org/10.1136/annrheumdis-2018-214952 Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Pedersen, D D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Lund Hetland, M 2020, ' Response to ''To switch or not to switch' : the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al ', Annals of the Rheumatic Diseases, vol. 79, no. 4 . https://doi.org/10.1136/annrheumdis-2018-214952
Glintborg, B, Sørensen, I J, Loft, A G, Lindegaard, H, Linauskas, A, Hendricks, O, Hansen, I M J, Jensen, D V, Manilo, N, Espesen, J, Klarlund, M, Grydehøj, J, Dieperink, S S, Kristensen, S, Olsen, J S, Nordin, H, Chrysidis, S, Dalsgaard Pedersen, D, Sørensen, M V, Andersen, L S, Grøn, K L, Krogh, N S, Pedersen, L & Hetland, M L 2017, ' A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis : 1-year clinical outcomes from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1426-1431 . https://doi.org/10.1136/annrheumdis-2016-210742 Glintborg, B, Sørensen, I J, Loft, A G, Lindegaard, H, Linauskas, A, Hendricks, O, Hansen, I M J, Jensen, D V, Manilo, N, Espesen, J, Klarlund, M, Grydehøj, J, Dieperink, S S, Kristensen, S, Olsen, J S, Nordin, H, Chrysidis, S, Dalsgaard Pedersen, D, Sørensen, M V, Andersen, L S, Grøn, K L, Krogh, N S, Pedersen, L, Hetland, M L & all departments of rheumatology in Denmark 2017, ' A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis : 1-year clinical outcomes from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1426-1431 . https://doi.org/10.1136/annrheumdis-2016-210742
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2019, ' To switch or not to switch : results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 78, no. 2, pp. 192-200 . https://doi.org/10.1136/annrheumdis-2018-213474 Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2019, ' To switch or not to switch: Results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry ', Annals of the Rheumatic Diseases, vol. 78, pp. 192-200 . https://doi.org/10.1136/annrheumdis-2018-213474
Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci ', Annals of the Rheumatic Diseases, vol. 79, no. 2, e14 . https://doi.org/10.1136/annrheumdis-2018-214788 Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Response to : 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB 4 : Possible fallout on non-medical switching' by Cantini and Benucci ', Annals of the Rheumatic Diseases, vol. 79, no. 2, e14 . https://doi.org/10.1136/annrheumdis-2018-214788 Glintborg, B, Loft, A G, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, D V, Nordin, H, Dalgaard, E B, Chrysidis, S, Kristensen, S, Raun, J L, Lindegaard, H, Manilo, N, Jakobsen, S H, Hansen, I M J, Dalsgaard Pedersen, D, Sørensen, I J, Andersen, L S, Grydehøj, J, Mehnert, F, Krogh, N S & Hetland, M L 2020, ' Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci ', Annals of the Rheumatic Diseases, vol. 79, no. 2, pp. e14 . https://doi.org/10.1136/annrheumdis-2018-214788